Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...
Molecular Matrix, a privately held company that arose from the University of California, Davis, received FDA approval for its Osteo-P bone graft substitute technology. Osteo-P is a non-mineralized, ...
Cerapedics Inc., a global, commercial-stage orthopedics company dedicated to redefining the path to bone repair, today announced U.S. Food and Drug Administration (FDA) approval for an expansion to ...
The narrative around bone health has long been dominated by a singular focus: calcium consumption. Yet despite widespread calcium supplementation, osteoporotic fractures affect approximately one in ...
Nine patients (6 male and 3 female, 30 to 64 years old) that were scheduled for elective removal of dorsal instrumentation hardware over a 12-month time period were included in our study. Indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results